--- a
+++ b/clusters/3009knumclusters/clust_296.txt
@@ -0,0 +1,664 @@
+History of allogeneic organ transplantation
+Have prior allogeneic bone marrow transplantation or solid organ transplant
+Patient must have a history of solid organ transplantation
+Prior treatment with any anti-PD-1 or anti-PD-L1 antibody, prior allogeneic bone marrow transplantation, or prior solid organ transplantation
+Patients who have received prior solid organ transplantation are not eligible
+Participants with prior allogeneic stem cell or solid organ transplantation
+Patients who have received a prior solid organ transplantation are not eligible
+Patients who have received a prior solid organ transplantation are not eligible
+Patients who have received a prior solid organ transplantation are not eligible
+Patients who have received a prior solid organ transplantation are not eligible
+Patients who have received a prior solid organ transplantation are not eligible
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+CRITERIA FOR ALLOGENEIC TRANSPLANTATION
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Patients who have received a prior solid organ transplantation are not eligible
+Patients who have received a prior solid organ transplantation are not eligible
+Patients who have received a prior solid organ transplantation are not eligible
+Patients who have received a prior solid organ transplantation are not eligible
+Patients who have received a prior solid organ transplantation are not eligible
+Patients who have received a prior solid organ transplantation are not eligible
+Patients with prior allogeneic bone marrow transplantation, double umbilical cord blood transplantation (dUCBT) or prior solid organ transplantation
+At least 6 weeks from autologous stem cell transplantation
+Prior allogeneic bone marrow or organ transplantation
+Prior allogeneic stem cell or solid organ transplantation
+Patient previously received allogeneic bone marrow or stem cell transplantation.
+Prior history of allogeneic stem cell transplantation
+Must be ineligible for high dose therapy/ stem cell transplantation
+History of allogeneic stem-cell (or other organ) transplantation
+History of bone marrow of solid organ transplantation
+7. Prior allogeneic bone marrow transplantation or prior solid organ transplantation;
+Prior organ allograft or allogeneic bone marrow transplantation
+Prior autologous or allogeneic organ or tissue transplantation
+Prior organ transplantation including allogenic stem cell transplantation
+Has a history of having undergone allogeneic stem cell transplantation, or any other allogeneic or xenogeneic transplant
+Has had any prior allogeneic solid organ or bone marrow transplantation.
+Prior allogeneic stem cell or solid organ transplantation;
+Autologous stem cell transplantation (SCT) within 100 days prior to first infusion
+Prior allogeneic SCT or solid organ transplantation
+Active or history of any serious autoimmune disease, prior organ transplantation, including allogeneic stem-cell transplantation or immune-deficiencies that required treatment with systemic immunosuppressive drugs and could flare-up during study treatment\r\n* (NOTE: Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible)
+Prior organ transplantation or allogeneic bone marrow transplantation.
+Eligible for Autologous Hematopoietic stem cell transplantation according at the investigator discretion.
+Prior allogeneic stem cell or solid organ transplantation
+Prior allogeneic stem-cell transplantation (SCT)
+Patients who received Allo-Stem cell Transplantation(Allo-SCT) within 12 months.
+History of allogeneic organ transplantation.
+Participant must not have a history of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic leukemia, solid organ transplantation, previous clinical diagnosis of tuberculosis, inflammatory bowel disease, or immune-mediated pneumonitis.
+History of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic leukemia, solid organ transplantation, or previous clinical diagnosis of tuberculosis.
+Patients with history of allogeneic stem cell transplantation
+Prior allogeneic or autologous bone marrow or organ transplantation
+Prior allogeneic stem cell or solid organ transplantation
+For rituximab in combination with polatuzumab vedotin and lenalidomide (R + Pola + Len) treatment group: R/R DLBCL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-CD20 monoclonal antibody in patients who are not eligible for autologous stem-cell transplantation or who have experienced disease progression following treatment with high-dose chemotherapy plus autologous stem-cell transplantation
+Prior allogeneic stem-cell transplantation (SCT), or autologous SCT within 100 days prior to Day 1 of Cycle 1
+Prior allogeneic or autologous bone marrow transplantation or other solid organ transplantation.
+Must not be eligible for high-dose therapy with autologous stem cell transplantation rescue
+History of solid organ or stem cell transplantation
+Participants must be recipients of an allogeneic bone marrow or stem cell transplantation with myeloablative or reduced intensity conditioning regimens
+No prior solid organ transplantation.
+Previous hematopoietic stem cell transplantation; patients can have had prior relapsed disease as long as they have never been previously transplanted
+Institutional criteria for and have institutional approval to undergo autologous peripheral blood stem cell transplantation
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Prior allogeneic stem cell or solid organ transplantation.
+Prior solid organ or bone marrow progenitor cell transplantation.
+Prior bone marrow or peripheral blood stem cell transplantation within the last 6 (six) months
+Prior allogeneic stem cell or solid organ transplantation
+NOTE: There is no limit to the prior number of chemotherapy regimens; patients with prior autologous or allogeneic stem cell transplantation, as well as prior therapy with cyclophosphamide or alemtuzumab, are eligible
+Patients are considered to have failed available therapies or to be ineligible for or to not be interested in intensive chemotherapies, including allogeneic hematopoietic stem cell transplantation
+History of organ transplantation including previous history of liver transplantation
+Subjects with prior autologous and allogeneic hematopoietic stem cell transplantation (allo HSCT) are eligible.
+Has undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years.
+Patients who have received a prior solid organ transplantation are not eligible
+Has ever received or is scheduled to receive an Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)
+Patients who have ever received an Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) ARE eligible.
+Patients who are scheduled to receive an Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) are NOT eligible
+Patients who have received a prior solid organ transplantation are not eligible
+Has failed to respond to, relapsed following, not eligible for, or opted not to participate in allogeneic stem cell transplantation
+Prior allogeneic stem cell or solid organ transplantation
+Patients who have received a prior solid organ transplantation are not eligible
+Receipt of any organ transplantation including autologous or allogeneic stem-cell transplantation.
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Prior allogeneic stem cell or solid organ transplantation
+Prior allogeneic bone marrow transplantation or solid organ transplant for another malignancy in the past
+Prior allogeneic hematopoietic stem cell transplantation (allo HSCT)
+Has had prior liver or other organ transplantation
+Patients who are candidates for allogeneic stem cell transplantation.
+Prior allogeneic stem cell transplantation (SCT), or autologous SCT within 100 days prior to Day 1 of Cycle 1
+Other high-risk hematologic malignancies eligible for stem cell transplantation per institutional standard
+History of organ transplantation
+Patients who have had an allogeneic hematopoietic stem cell transplantation are not eligible.
+Prior allogenic stem cell or solid organ transplantation
+Prior stem-cell transplantation (SCT).
+Patient has an appropriate donor identified for hematopoietic stem cell transplantation
+Deemed eligible for autologous stem cell transplantation (ASCT) by standard institutional criteria
+Has undergone prior allogenic hematopoietic stem cell transplantation.
+Solid tumor transplantation.
+Patients with prior allogeneic stem cell or solid organ transplantation.
+Receipt of any organ transplantation including allogeneic stem-cell transplantation.
+EXCLUSION - DURVALUMAB DRUG-SPECIFIC: History of allogenic organ transplantation.
+Prior allogenic hematopoietic stem cell transplantation.
+Receipt of any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that do not require immunosuppression (e.g., corneal transplant, hair transplant).
+Will undergo first allogeneic hematopoietic stem cell transplantation (HSCT) for their malignancy. Conditioning may have been either conventional myeloablative (MAC) or reduced intensity conditioning (RIC)
+Prior organ transplantation including allogenic stem-cell transplantation
+History of solid organ transplantation.
+No major organ dysfunction precluding transplantation.
+Patients who are candidates for allogeneic transplantation, have a suitable donor, and are willing to undergo transplantation
+Relapsed patients who have undergone autologous or allogeneic hematopoietic stem cell transplantation previously
+Patients with psychological or medical condition that patient's physician deems unacceptable to proceed to allogeneic hematopoietic stem cell transplantation
+Receipt of any organ transplantation, including allogeneic stem-cell transplantation, except of transplants that do not require immunosuppression (e.g., corneal transplant, hair transplant)
+Prior allogeneic stem cell or solid organ transplantation
+Prior allogeneic stem cell transplantation
+Cohort #1: considered eligible for high-dose chemotherapy followed by autologous stem cell transplantation (ASCT)
+For cohort 1 (DLBCL) only: prior organ transplantation including allogeneic stem-cell transplantation
+Receipt of any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that do not require immunosuppression (e.g., corneal transplant, hair transplant).
+Participants must not have had prior organ allograft or allogeneic bone marrow transplantation
+History of allogenic organ transplantation.
+Participants must be designated to undergo reduced intensity allogeneic peripheral blood (PB) or bone marrow (BM) hematopoietic stem cell transplantation. Consent will be obtained prior to admission for HCT
+Receipt of any organ transplantation requiring ongoing immunosuppression
+Subject is a candidate for hematopoietic stem cell transplantation (HSCT).
+Prior solid organ transplantation.
+Prior solid organ transplantation.
+Has undergone solid organ transplant at any time, or prior allogeneic hematopoietic stem cell transplantation within the last 5 years
+MEDICATION-RELATED: Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation.
+Prior organ transplantation including allogenic stem-cell transplantation within 3 months prior to planned enrollment.
+Patients who have received a prior solid organ transplantation are not eligible
+History of corneal transplantation
+Prior allogeneic stem cell or solid organ transplantation
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Patients who have received a prior solid organ transplantation are not eligible
+High-dose chemotherapy followed by stem cell transplantation (autologous or allogeneic).
+History of primary immunodeficiency, allogeneic bone marrow transplantation, solid organ transplantation, or previous clinical diagnosis of tuberculosis
+History of prior allogeneic bone marrow, stem-cell, or solid organ transplantation
+Prior organ allograft or allogeneic bone marrow transplantation
+Prior allogeneic stem cell or solid organ transplantation
+Prior organ transplantation, including allogeneic stem cell transplantation
+Prior autologous or allogeneic stem cell transplantation
+History of organ, bone marrow, or stem cell transplantation
+Prior allogeneic stem cell or organ transplantation including corneal transplant
+Prior allogeneic bone marrow transplantation or prior solid organ transplantation.
+Prior allogeneic stem cell or solid organ transplantation
+Patients who in the opinion of the treating physician are unlikely to comply with the restrictions of allogeneic stem cell transplantation based on formal psychosocial screening
+Receipt of any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that do not require immunosuppression (e.g. corneal transplant, hair transplant)
+Prior organ transplantation including allogenic stem-cell transplantation
+Prior allogeneic transplantation
+History of solid organ or stem cell transplantation
+Prior organ transplantation including allogeneic stem cell transplantation, brain metastases (except those meeting certain protocol specified criteria which are acceptable), significant acute or chronic infections, a history of cardiovascular/cerebrovascular disease.
+History of allogeneic stem?cell (or other organ) transplantation
+Previous allogeneic or autologous hematopoietic cell transplantation or solid organ transplantation
+High dose chemotherapy followed by autologous stem cell transplantation within 90 days prior to initiating study treatment;
+Is eligible for intensive chemotherapy and/or allogeneic stem cell transplantation. The reason a participant is not eligible for intensive chemotherapy and/or allogeneic stem cell transplantation may consist of one or more of the following factors:
+Has a history of allogeneic stem cell transplantation
+Prior organ transplantation including allogeneic stem cell transplantation
+Prior cell or gene therapy, excluding transfers of genetically unmodified autologous cells (eg. Hematopoietic stem cell transplantation), at any time; or prior allogeneic HSCT at any time
+Patients who have had a liver or any organ transplantation
+Subjects who have opted not to undergo allogeneic hematopoietic stem cell transplantation and who are not deemed eligible for high intensity chemotherapy.
+Prior history of allogeneic hematopoietic stem cell transplantation.
+Patients with prior orthotropic liver transplantation
+Prior organ transplantation including allogenic stem-cell transplantation.
+Has a history of allogeneic stem cell transplantation
+Immunosuppression following a Hematopoietic Stem Cell Transplantation (HSCT) within 6 weeks prior to study entry;
+Participants with prior allogeneic stem cell or solid organ transplantation
+Prior stem cell transplantation for myeloma
+Patients with prior solid organ transplantation on anti-immunosuppressant
+Prior organ transplantation including allogenic stem-cell transplantation
+History of allogeneic organ transplantation
+Prior organ transplantation including allogeneic stem-cell transplants
+(Atezolizumab-related exclusion) Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Patients who are candidate for an autologous or allogeneic stem cell transplantation (SCT) will be allowed to receive the study drugs as a “bridge” to transplantation if candidates for transplant
+Allogeneic hematopoietic cell transplantation within 5 years of study drug administration
+Patients with a prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Patients with HL or DLBCL must refuse or not be candidates for curative autologous stem cell transplantation
+Has history of solid organ transplantation
+Allogeneic hematopoietic stem cell transplantation (HSCT) within 24 weeks before the start of protocol-specified therapy.
+DONOR: Has undergone solid organ, stem cell, bone marrow or blood transplantation
+Prior allogeneic bone marrow transplantation or prior solid organ transplantation
+PHASE I: Patients who underwent an allogeneic hematopoietic stem cell transplantation from any donor source for acute lymphocytic leukemia
+PHASE I: Patients who are between T+40 and T+100 after allogeneic transplantation
+PHASE II: Patients who underwent an allogeneic hematopoietic stem cell transplantation from any donor source for acute lymphocytic leukemia
+Prior history of stem cell transplantation
+Prior allogeneic stem cell transplantation (ASCT) or other anti-CD22 immunotherapy within =< 4 months before first dose of study treatment
+Prior organ transplantation including allogeneic stem-cell transplantation
+Prior organ transplantation, including allogeneic stem cell transplantation
+Either not eligible or unwilling to proceed with hematopoietic stem cell transplantation (HSCT)
+Prior organ transplantation including allogenic stem-cell transplantation
+Prior organ transplantation, including allogeneic stem cell transplantation
+Eligible for, have a suitable donor, and are willing to undergo hematopoietic stem cell transplantation (HSCT)
+Patients with a prior history of allogeneic stem cell or solid organ transplantation
+Patients with aggressive NHL must have failed autologous hematopoietic stem cell transplantation (HSCT), or are ineligible or not consenting to autologous HSCT
+Prior allogeneic bone marrow or peripheral blood stem cell transplantation
+Candidate for second autologous stem cell transplantation per local institution’s guidelines with at least 2 x 10^6/kg CD34+ autologous stem cells available for transplantation
+More than one prior transplant prior to study entry with the exception of tandem transplantation; tandem transplantation is defined as two autologous stem cell transplants that occur within 9 months of one another, and the patient did not have disease progression in the period between the two transplants
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Prior organ transplantation
+Prior autologous or allogeneic stem cell transplantation
+Prior treatment with chimeric antigen receptor (CAR) T cells or other forms of adoptive cellular therapy, with the exception of autologous stem cell transplantation
+Must have undergone allogeneic hematopoietic stem cell transplantation (HSCT) (regardless of stem cell source)
+History of prior autologous hematopoietic cell transplantation
+History of corneal transplantation
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Prior hematopoietic transplantation is allowed (autologous and/or allogeneic)
+Prior stem cell transplantation
+Prior allogeneic bone marrow or organ transplantation
+History of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic leukemia, solid organ transplantation, or previous clinical diagnosis of tuberculosis.
+Receipt of any organ transplantation including allogeneic stem-cell transplantation
+Autologous stem cell transplantation within 12 weeks before the starting IP treatment or past history of allogeneic stem cell transplantation.
+Has undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years
+History of organ transplantation
+Previous allogeneic hematopoietic stem cell transplantation
+No major organ dysfunction precluding transplantation
+Patients who have received a prior solid organ transplantation are not eligible
+Patients with any of the following hematologic malignancies who are considered to be eligible for allogeneic transplantation:
+Patient participants who have undergone autologous stem cell transplantation (autoSCT) are eligible provided that they are >= 4 weeks from stem cell infusion
+Patients with prior stem cell transplantation or solid organ transplantation.
+No prior allogeneic bone marrow or organ transplantation
+Patients are planned for treatment with high dose melphalan and autologous hematopoietic cell transplantation (HCT)
+Prior history of allogeneic hematopoietic cell transplantation
+History of primary immunodeficiency, solid organ transplantation, or previous clinical diagnosis of tuberculosis
+Autologous stem cell transplantation within 12 weeks prior to study entry
+Have undergone allogeneic stem cell transplantation
+Relapsed after allogeneic transplantation
+Patients who have previously received solid organ transplantation are NOT eligible for either Stratum
+No plan for allogeneic stem cell transplantation within 3 months
+History of allogenic organ transplantation
+Prior hematopoietic transplantation is allowed (autologous and/or allogeneic)
+Prior hematopoietic stem cell or bone marrow transplantation
+History of solid organ transplantation
+History of organ transplantation
+Patients who have undergone allogeneic stem cell transplantation and have required systemic treatment for GVHD (including but not limited to oral or parenteral corticosteroids, ibrutinib, and extracorporeal phototherapy) within the last 12 weeks
+Not suitable for, or declined high dose chemotherapy and autologous stem cell transplantation (ASCT).
+Prior hematopoietic allogenic stem cell transplantation.
+Prior autologous stem cell transplantation.
+Patients who have received prior stem cell transplantation will be allowed to enroll as long as prior transplantation has been at least 3 months before enrollment in the trial and any transplant related toxicities have subsided to grade 1 or less
+Subjects must not have undergone allogeneic stem cell transplantation
+Patients with prior allogeneic stem cell or solid organ transplantation
+Prior treatment with allogeneic stem cell transplantation
+History of allogenic organ transplantation that requires use of immunosuppressive agents.
+Prior hematopoietic stem cell or bone marrow transplantation
+Patients who have received a prior solid organ transplantation are not eligible
+Having received a solid organ transplantation
+Have undergone organ transplantation including allogeneic or autologous stem-cell transplantation, at any time;
+Has undergone prior allogeneic hematopoetic stem cell transplantation within the last 5 years
+Patients who have undergone allogeneic stem cell transplantation
+Patients who have undergone autologous stem cell transplantation within 3 months from study entry
+Tandem autologous transplantation
+Individuals who are eligible for allogeneic hematopoietic stem cell transplantation (HSCT) as determined by the treating physician, and have a suitable donor or appropriate stem cell source available
+Patients who have undergone prior autologous stem cell transplantation or allogeneic transplantation
+They must not have a history of solid organ transplantation.
+Study enrollment no earlier than 3 months after preceding hematopoietic cell transplantation (HSCT)
+Patients with B-lineage ALL at least marrow CR in Salvage 1 and beyond with molecular failure at any time point after 1 month of salvage therapy are allowed, including patients who received prior allogeneic stem cell transplantation
+Patients who have poor or no graft function post stem cell transplantation
+Patients with a prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Subjects who have received prior solid organ transplantation are not eligible
+Prior allogeneic bone marrow or organ transplantation
+Patients who have received a solid organ transplantation are not eligible.
+Allogeneic stem cell transplantation within 6 months, or has active GVHD requiring ongoing immunosuppression.
+Prior high dose chemotherapy for autologous hematopoietic cell transplantation or prior allogeneic transplantation
+Prior allogeneic or autologous transplantation
+Prior allogeneic stem cell transplantation
+Patients with history of organ and allogeneic stem cell transplantation
+Prior allogeneic hematopoietic progenitor cell transplantation
+Prior autologous hematopoietic progenitor cell transplantation if the conditioning regimen included total body irradiation
+Transplantation for AML (allogeneic or autologous) allowed unless within 90 days of study entry
+Patients with psychological or medical condition that patient's physician deems unacceptable to proceed to allogeneic hematopoietic stem cell transplantation
+Patients should have received single autologous stem cell transplantation 60-120 days prior to enrollment to the trial
+History of organ transplantation
+Patient diagnosed with hepatocellular carcinoma and listed for orthotopic liver transplantation at the participating institution in accordance with Organ Procurement and Transplantation Network (OPTN) guidelines
+DIAGNOSIS REQUIREMENT FOR PHASE I PATIENTS: High-risk AML (by European Leukemia Net [ELN] criteria) in complete remission (CR) and has either refused hematopoietic stem cell transplantation OR is currently not eligible for hematopoietic stem cell transplantation OR for whom hematopoietic stem cell transplantation is being reserved for later relapse; this is inclusive of patients with minimal residual disease evidenced by cytogenetics, molecular testing, and/or flow cytometry OR
+Relapsed after allogeneic transplantation
+Patients must be eligible to undergo autologous stem cell transplantation by standard institutional criteria
+Patient has history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Patients with B-cell hematological malignancies who are eligible for allogeneic transplantation
+History of bone marrow or stem cell transplantation (allogeneic or autologous)
+Prior allogeneic marrow or stem cell transplantation.
+Prior solid organ transplantation
+At least 60 days from day of transplantation
+Malignant conditions for which CD34+ selected, T-cell depleted allogeneic hematopoietic stem cell transplantation is indicated such as:
+-  Participant is not a candidate to undergo intensive chemotherapy or allogeneic hematopoietic stem cell transplantation (HSCT).
+Participant has received allogeneic HSCT or solid organ transplantation.
+Allowed prior allogeneic hematopoietic stem cell transplantation (allo-HCT) regardless of stem cell source; patients must be at least 3 months post allo-HCT (at time of treatment start); mismatched transplantations would be allowed
+Prior autologous or allogeneic organ or tissue transplantation
+Prior autologous or allogeneic hematopoietic cell transplantation (other than autologous SCT 60-120 days prior to registration)
+Minimum donor and stem cell requirements for high-risk patients undergoing stem cell transplantation:
+Prior allogeneic or autologous bone marrow transplantation or other solid organ transplantation.
+Previous history of autologous or allogeneic blood stem cell transplantation or solid organ transplantation
+Patients eligible for hematopoietic stem cell transplantation
+Patients considered for transplantation must have a sufficient graft as based on current criteria of the University of Minnesota Blood and Marrow Transplantation Program
+Time available (at least 12 weeks) for treatment of hepatitis C prior to autologous or allogeneic transplantation
+History of allogeneic organ transplantation
+Receipt of any organ transplantation
+History of allogeneic organ transplantation.
+History of allogeneic stem cell transplantation, prior solid organ transplant, or anticipated to undergo solid organ transplantation, or left ventricular assist device (LVAD) implantation, during the course of the study.
+Patients with prior stem cell transplantation or solid organ transplantation.
+Patients who have received prior allogeneic stem cell-transplantation
+Patients who have undergone a stem cell transplantation.
+History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
+Prior autologous or allogeneic organ or tissue transplantation
+Patients who have had a prior stem cell transplantation are NOT eligible for participation
+Prior autologous or allogeneic transplantation for any disease
+Prior organ transplantation including allogenic stem-cell transplantation.
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Patients with a prior history of allogeneic stem cell or solid organ transplantation
+Prior allogeneic stem cell or solid organ transplantation
+No prior autologous or allogeneic organ or tissue transplantation
+Prior allogeneic bone marrow transplantation
+Prior hematopoietic stem cell or bone marrow transplantation
+Autologous stem cell transplantation less than 90 days prior to study day 1
+Prior stem cell transplantation or solid organ transplantation
+History of organ or previous autologous/allogeneic stem cell transplantation
+No 10/10 matched sibling donor available or not financially eligible for allogeneic stem cell transplantation
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation.
+Prior hematopoietic stem cell or bone marrow transplantation.
+Subjects who have received prior solid organ transplantation are not eligible
+History of allogeneic organ transplantation.
+Prior hematopoietic cell transplantation allogeneic or autologous (A prior autologous HCT will be allowed as long as it was part of tandem transplantation).
+Prior allogeneic hematopoietic stem cell transplantation within previous 100 days
+Prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Stem cell transplantation
+Prior allogeneic (allo)-hematopoietic cell transplantation (HCT) less than three months from the time of enrollment
+Patients who have received prior stem cell transplantation will be allowed to enroll as long as prior transplantation has been at least 3 months before enrollment in the trial and any transplant related toxicities have subsided to grade 1 or less
+Prior organ allograft or allogeneic transplantation.
+Patients who have received prior solid organ transplantation are not eligible
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Patients who have received allogeneic hematopoietic stem cell transplantation are ineligible
+Prior allogeneic stem cell or solid organ transplantation
+History of organ transplantation
+Prior allogeneic hematopoietic cell transplantation
+History of prior allogeneic bone marrow, stem-cell or solid organ transplantation.
+ALLOGENEIC TRANSPLANTATION:
+History of allogenic organ transplantation
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Prior solid organ transplantation
+History of organ transplantation
+ARM A: History of bone marrow or solid organ transplantation
+ARM B: History of bone marrow or solid organ transplantation
+History of organ transplantation
+Subjects who are candidates for allogeneic transplantation, have a suitable donor, and are willing to undergo transplantation
+Myeloablative or non-myeloablative allogeneic hematopoietic cell transplantation
+No prior myeloablative therapy or hematopoietic cell transplantation
+History of organ transplantation
+Prior organ allograft or allogeneic transplantation
+Prior organ allograft or allogeneic transplantation, if the transplanted tissue is still in place
+Subjects who have had solid organ or bone marrow transplantation
+Prior allogeneic transplantation
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Have received or are ineligible for immediate established curative regimens, including stem cell transplantation
+Patients who have undergone autologous stem cell transplantation (ASCT) are eligible provided that they are >= 4 weeks from stem cell infusion and meet other eligibility criteria
+Eligible for autologous transplantation
+Previous stem cell collection or transplantation (autologous or allogeneic)
+History of allogeneic stem cell transplantation
+Patients who have received a prior solid organ transplantation are not eligible
+Patients who have received a prior solid organ transplantation are not eligible
+Prior high-dose chemotherapy and autologous hematopoietic cell transplantation (HCT)(s) is (are) allowed
+Patients who have received a prior solid organ transplantation are not eligible
+Prior organ allograft or allogeneic transplantation, if the transplanted tissue is still in place
+Patients who have received a prior solid organ transplantation are not eligible
+Prior allogeneic stem cell transplantation
+Patients will have completed induction therapy, achieved 1st CR and will have completed any planned post-remission therapy; patients are not candidates for allogeneic stem cell transplantation; for purposes of this study, patients who are not candidates for allogeneic stem cell transplantation shall be defined as 1) those who do not meet the eligibility criteria of an open allogeneic transplant protocol or 2) those who do not have a suitable available human leukocyte antigen (HLA) matched donor available or 3) those who refuse to undergo stem cell transplantation or 4) those patients whose disease is characterized by \good risk\ features (for AML the following cytogenetic subtypes: t(8;21), inv(16), or t(16;16), t(15;17), normal karyotype with mutated nucleophosmin (NPM1) and negative for tandem duplication of fms-related tyrosine kinase 3 (FLT-3); for ALL: T cell phenotype of any B lineage disease exclusive of t(9;22) or t(4;11) in whom allogenic stem cell transplantation in 1st CR would not be offered as standard of care\r\n* Alternatively, those patients greater than or equal to 60 years of age who have achieved 1st CR and in whom no further postremission chemotherapy is planned may be enrolled
+Patients who have undergone autologous or allogeneic stem cell transplantation
+Prior allogeneic stem cell transplantation
+Prior autologous or allogeneic hematopoietic stem cell transplantation (HSCT)
+History of major organ transplantation
+History of major organ transplantation
+Requirement of re-transplantation for primary non function
+Have undergone first allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies. Recipients of nonmyeloablative and myeloablative conditioning regimens are eligible.
+Completion of, if applicable, an autologous stem cell transplantation (ASCT) at least 3 months prior to first dose of study drug.
+Prior allogeneic stem cell transplantation (SCT) within the last 5 years.
+Has undergone prior allogeneic hematopoetic stem cell transplantation within the last 5 years.
+Allogeneic hematopoietic stem cell transplantation within the last 5 years.
+Prior allogeneic stem-cell transplantation is excluded.
+Not a candidate for curative therapy or hematopoietic stem-cell transplantation (either due to disease burden, fitness, or preference).
+Patients deemed clinically eligible for allogeneic stem cell transplantation.
+Prior organ transplantation, including allogeneic stem-cell transplantation
+Participants with prior bone marrow or solid organ transplantation.
+Has undergone prior organ or allogeneic hematopoetic stem cell transplantation
+Has received autologous stem cell transplantation (ASCT) within 12 weeks before the date of randomization.
+Prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Prior organ allograft or allogeneic transplantation, if the transplanted tissue is still in place
+Participant must be ineligible or unwilling to undergo stem cell transplantation at time of study entry
+Prior allogeneic stem cell or solid organ transplantation
+Patients who have undergone autologous hematopoietic stem cell transplantation are eligible once they have recovered from all toxicities from therapy
+Subjects has history of organ or allogeneic stem cell transplantation
+Have had at least 60 days between prior hematopoietic stem cell transplantation (SCT) and first dose of study drug.
+Any BM relapse after allogeneic stem cell transplantation (SCT) and must be ? 6 months from SCT at the time of CTL019 infusion OR.
+Prior allogeneic bone marrow or solid organ transplantation
+Hematopoietic stem cell transplantation ? 4 months of dosing
+History of corneal transplantation
+History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
+Prior bone marrow or stem cell transplantation
+Inability to comply with the requirements for care after allogeneic stem cell transplantation
+Prior allogeneic stem cell or solid organ transplantation
+Has undergone prior organ or allogeneic hematopoetic stem cell transplantation
+Prior allogeneic hematopoietic stem-cell transplantation or prior solid-organ transplantation
+History of myelodysplastic syndrome or solid organ transplantation
+Participants with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Prior organ transplantation, including allogeneic stem-cell transplantation
+Participants with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Patients must NOT have received autologous or allogeneic stem cell transplantation
+Prior hematopoietic stem cell or bone marrow transplantation
+Prior allogeneic stem-cell transplantation (SCT)
+History of solid organ transplantation
+No known prior organ allograft or allogeneic transplantation
+have undergone previous allogenic stem cell transplantation
+Prior allogeneic stem cell transplantation (SCT)
+Eligible for curative treatment (ablation or transplantation)
+Prior allogeneic stem cell or solid organ transplantation
+Patient has a history of hematological malignancy within the last 5 years prior to study entry; prior allogeneic bone marrow transplantation or prior solid organ transplantation
+History of bone marrow, stem cell, or allogenic organ transplantation
+Had solid organ or bone marrow transplantation
+Subject who has history of organ transplant or allogeneic hematopoietic stem cell transplantation.
+Eligible for autologous stem cell transplantation
+Prior allogeneic transplantation
+Has received more than 1 hematopoietic stem cell transplantation.
+Subjects with relapsed primary disease, or subjects who have been treated for relapse after the allogeneic hematopoietic stem-cell transplantation (allo-HSCT) was performed.
+Eligible for allogenic stem cell transplantation.
+History of solid organ transplantation
+Prior organ transplantation including allogenic stem cell transplantation.
+History of allogeneic stem cell or solid organ transplantation
+Prior solid organ transplantation
+Prior allogeneic bone marrow or organ transplantation
+Prior allogeneic stem cell transplantation
+The subject must not be a candidate for potentially curative therapy including hematopoietic stem cell transplantation, except where one of the standard therapy regimen combinations may be used prior to transplantation per standard medical practice
+Eligible for allogeneic bone marrow or stem cell transplantation
+Prior stem cell or bone marrow transplantation
+Patients that have received prior allogeneic stem cell transplantation are excluded from this study
+History of solid organ, allogeneic bone marrow, or stem cell transplantation within the 6 months prior to consent.
+Prior stem cell transplantation allogeneic or autologous
+Have had organ allograft or hematopoietic transplantation.
+Receipt of any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that do not require immunosuppression (eg, corneal transplant, hair transplant)
+Autologous stem cell transplantation (SCT) within 100 days prior to study drug, or any prior allogeneic SCT or solid organ transplantation
+Any previous autologous hematopoietic stem cell transplantation (HSCT) must have occurred at least 3 months prior to start of conditioning
+Prior allogeneic bone marrow transplantation or solid organ transplant
+Diagnosed with AML and eligible for standard induction chemotherapy or stem cell transplantation
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Prior organ transplantation, including allogeneic stem cell transplantation
+Subject has had or has planned to receive any organ transplantation;
+For rituximab + Atezo + Pola treatment group: relapsed or refractory DLBCL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-CD20 monoclonal antibody, in participants who are not eligible for second line combination (immuno-) chemotherapy and autologous stem-cell transplantation or who have failed second line combination (immuno-) chemotherapy or experienced disease progression following autologous stem-cell transplantation
+Prior allogeneic stem cell transplantation (SCT), completion of autologous SCT within 100 days prior to Day 1 of Cycle 1 (D1C1)
+Eligible for autologous stem cell transplantation
+AML participants < 60 years old must be in second or further relapse or relapsing after allogeneic stem cell transplantation regardless of number of relapses
+Has received high dose chemotherapy followed by autologous stem cell transplantation less than 90 days prior to first dose of study treatment
+Subjects who have had solid organ or bone marrow Transplantation.
+Prior treatment with stem cell transplantation
+Prior stem cell transplantation (autologous or allogeneic)
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Prior allogeneic bone marrow or organ transplantation.
+Prior allogeneic hematopoietic stem cell transplantation
+Patients who have received liver transplantation
+Active graft versus host disease (GVHD) after allogeneic stem cell transplantation; at least 2 months must have elapsed since completion of an allogeneic stem cell transplantation
+History of organ transplantation.
+History of allogeneic organ transplantation;
+Prior allogeneic bone marrow or organ transplantation
+Prior hematopoietic stem cell transplantation
+Prior organ allograft or allogeneic transplantation, if the transplanted tissue is still in place
+History of primary immunodeficiency, solid organ transplantation, or tuberculosis
+Prior allogeneic bone marrow or organ transplantation
+History of allogeneic organ transplantation
+Participants who are newly diagnosed and not considered candidate for high-dose chemotherapy with stem cell transplantation (SCT) due to: being age >=65 years, or in participants <65 years: presence of important comorbid conditions likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation
+History of prior allogeneic bone marrow progenitor cell or solid organ transplantation.
+Research participant has an indication to be considered for autologous stem cell transplantation
+Participants with prior allogeneic stem cell or solid organ transplantation
+The patient has received any hematopoietic stem cell transplantation (HSCT) ? 3 months prior to start of Investigational Product.
+The patient has received allogeneic hematopoietic stem cell transplantation (HSCT) ? 3 months or autologous HSCT ? 21 days prior to start of Investigational Product (IP).
+Allogeneic stem cell transplantation
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Prior organ transplantation including allogenic stem-cell transplantation.
+Prior allogeneic bone marrow or organ transplantation
+Prior allogeneic bone marrow or organ transplantation
+Subjects who relapse after allogeneic transplantation;
+Prior allogeneic stem cell transplantation
+Patients who are immunocompromised as listed as follows:\r\n* Human immunodeficiency virus positivity\r\n* Chronic administration (defined as daily or every other day for continued use > 14 days) of systemic corticosteroids (including steroid eye drops) or other immune suppressive drugs, within 28 days before the first planned dose of PSA-TRICOM; nasal, or inhaled steroid, and topical steroid creams for small body areas are not excluded\r\n* Patients who have undergone allogeneic peripheral stem cell transplantation, or solid organ transplantation requiring immunosuppression \r\n* History of splenectomy
+Patient is considered for autologous stem cell transplantation with full dose melphalan (200 mg/m^2)
+Patients previously treated with autologous or allogeneic bone marrow or stem cell transplantation are ineligible
+Patients who have received a prior solid organ transplantation are not eligible
+Patients with relapsed multiple myeloma following autologous stem cell transplantation who achieved < partial response following additional chemotherapy or who achieved < partial response (PR) at 3 months following autologous stem cell transplantation and patients with plasma cell leukemia at diagnosis
+Recipients of prior allogeneic hematopoietic stem cell transplantation
+History of organ transplantation
+Previous allogenic stem cell transplantation.
+Hematopoietic cell transplantation (HCT) recipients
+Patient must not have had a prior allogeneic bone marrow or organ transplantation
+Patients must be between 100 - 200 days after allogeneic stem cell transplantation
+Patients with relapsed or refractory disease following stem cell transplantation are permitted
+Patient must have no history of organ transplantation or ongoing immunosuppressant therapy
+Patients who have undergone prior stem cell transplantation will not be excluded from study entry; at least 3 months must have elapsed since autologous or allogeneic stem cell transplantation; patients must have no evidence of active graft versus host disease
+Prior allogeneic bone marrow or organ transplantation
+Patients previously treated with allogeneic bone marrow or stem cell transplantation are ineligible
+Patients who are immediate candidates for allogeneic bone marrow or stem cell transplantation; patients who refuse this option remain eligible and need to be documented as such in patient medical record
+Patients who are eligible for autologous transplantation
+Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation
+Patient who has undergone allogeneic stem cell transplantation
+Day > 100 after allogeneic hematopoietic stem cell transplantation
+Phase I: Patients with diagnosis of multiple myeloma at any stage of disease undergoing high dose chemotherapy and stem cell transplantation; Phase II: Patients with myeloma undergoing a first high dose chemotherapy and stem cell transplantation after achieving at least stable disease following induction therapy; any induction regimen prior to transplantation is allowed; no more than 2 prior lines of therapy prior to transplantation are allowed
+Patients who have undergone prior allogeneic hematopoietic stem cell transplantation
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Prior organ transplantation including allogenic stem-cell transplantation
+Receipt of any organ transplantation, including allogeneic stem-cell transplantation.
+Had organ transplantation
+Subjects must be relapsed/refractory. Prior stem cell transplantation is allowed.
+History of any organ transplantation
+History of allogeneic stem cell transplantation
+Patients that underwent allogeneic transplantation as a treatment of graft failure
+Eligibility for potentially-curative therapy including hematopoietic stem-cell transplantation
+Patients with prior allogeneic solid organ transplantation
+Progressive disease within 8 weeks of prior therapy or within 12 weeks after prior autologous stem cell transplantation
+Greater than approximately 6 months since autologous stem cell transplantation
+No prior autologous or allogeneic hematopoietic cell transplantation
+History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
+History of organ transplantation.
+Prior solid organ or bone marrow progenitor cell transplantation.
+Subjects with AML in their first relapse following a remission >12 months in duration who are eligible for standard therapies (e.g. chemotherapy or stem cell transplantation);
+Patients that underwent allogeneic transplantation as a treatment of graft failure
+History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
+Patients who have undergone autologous/allogeneic stem cell transplantation are eligible
+History of organ transplantation
+Previous hematopoetic stem cell transplantation.
+Recipient of an hematopoietic stem cell transplantation (HSCT)
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Patients with neutropenic fever who have existing malignancy or have undergone hematopoietic stem cell transplantation
+Patients must meet institutional criteria for eligibility for non-myeloablative allogeneic stem cell transplantation
+There are no liver function test criteria for non-myeloablative allogeneic stem cell transplantation
+Prior allogeneic bone marrow or organ transplantation
+Patients who are candidates for autologous stem-cell transplantation due to primary refractory or first relapse of disease
+Subjects with hematologic malignancies for whom allogeneic stem cell transplantation is deemed clinically appropriate.
+At the time of registration, stem cell transplantation is not planned within the next 3 months
+Previous allogeneic stem-cell transplantation
+Less than 1 month since completion of autologous stem cell transplantation or less than 3 months since completion of allogeneic stem cell transplantation
+Prior bone marrow or organ transplantation.
+Patients with a history of solid organ transplantation
+History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
+history of allogeneic stem cell or solid organ transplantation.
+Prior history allogeneic stem cell transplantation
+Must be eligible for autologous transplantation according to institutional guidelines
+Prior allogeneic bone marrow or organ transplantation
+Prior allogeneic bone marrow or peripheral blood stem cell transplantation
+Prior allogeneic stem cell or solid organ transplantation
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Prior allogeneic stem cell transplantation (SCT), or autologous SCT within 100 days prior to Day 1 of Cycle 1
+History of allogeneic stem cell transplantation
+History of allogeneic stem cell transplantation
+Prior allogeneic stem cell transplantation
+Participant who has a history of organ transplantation.
+Patients who are candidates for allogeneic stem cell transplantation (for patients with refractory or relapsed acute myeloid leukemia).
+Prior autologous or allogeneic stem cell transplantation
+Prior allogeneic bone marrow or solid organ transplantation
+Subject needs heart transplantation.
+History of previous bone marrow and/or stem cell transplantation.
+History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
+Prior allogeneic stem cell or solid organ transplantation
+Significant organ dysfunction deemed to be inappropriate for autologous transplantation
+History of myelodysplastic syndrome, allogeneic stem cell or solid organ transplantation
+Not eligible for an allogeneic hematopoietic stem cell transplantation
+History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
+Prior bone marrow/hematopoietic stem cell transplantation
+History of solid organ, bone marrow, or progenitor cell transplantation
+Prior organ transplantation
+At least 60 days must have elapsed from hematopoietic stem cell transplantation (HSCT)
+Prior allograft transplantation including liver transplantation.
+Eligible for autologous transplantation
+Prior allogeneic or autologous bone marrow or organ transplantation that requires use of immunosuppressives
+Allogeneic hematopoietic stem cell transplantation (HSCT) within 12 weeks before blinatumomab treatment
+History of allogeneic stem-cell (or other organ) transplantation
+Eligible for autologous stem cell transplantation
+Lenalidomide must have been used for at least 6 months after autologous hematopoietic stem cell transplantation with the current dose of lenalidomide 15 mg/day or less
+Prior therapy with severely myelotoxic regimens, including autologous and allogenic stem cell transplantation
+Histologically confirmed (Myelodysplastic Syndromes) MDS or Acute Myeloid Leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT) with either peripheral blood or bone marrow as the source of hematopoietic stem cells At the time of allogeneic HSCT:
+Prior allogeneic bone marrow or organ transplantation
+Not a candidate for allogeneic stem cell transplantation
+Patients who have received allogeneic stem cell transplantation < 12 months prior to entering the study
+Immunocompromised, as defined by one of the following: Autologous or Allogeneic hematopoietic cell transplantation (HSCT); Lung or lung-heart transplantation; Subjects treated with chemotherapy for hematologic malignancies; Subjects treated with chemotherapy for solid tumor malignancies
+Subjects may not have had prior organ allograft or allogeneic bone marrow transplantation
+Patients who have undergone T-cell depleted allogeneic hematopoietic stem cell transplantation at Memorial Sloan-Kettering Cancer Center (MSKCC) for:
+History of primary immunodeficiency, solid organ transplantation, or tuberculosis
+Prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Patients with active graft versus host disease after allogeneic stem cell transplantation. At least 3 months must have elapsed since completion of allogeneic stem cell transplantation except for patients with AML, where at least 2 months must have elapsed;
+Allogeneic stem cell transplantation
+Previous autologous or allogeneic stem cell transplantation.
+Prior organ allograft or allogeneic bone marrow transplantation
+Patients must have relapsed or progressed after at least one prior cytotoxic chemotherapy\r\n* Previous autologous or allogeneic stem cell transplantation is permitted\r\n* Previous treatment with either single agent panobinostat or lenalidomide is permitted
+Patients who are candidates for high dose chemotherapy and autologous stem cell transplantation with curative intent should not be enrolled
+History of previous bone marrow and/or stem cell transplantation.
+Prior allogeneic stem cell transplantation.
+Previous allogeneic stem cell transplantation at any time OR autologous stem cell transplantation within 6 months of study entry.
+Prior hematopoietic stem cell or bone marrow transplantation
+Has received a prior allogeneic organ or tissue transplantation
+The participant has received a prior autologous or allogeneic organ or tissue transplantation.
+Previous autologous stem cell transplantation within 6 months prior to randomization.
+Previous allogeneic stem cell transplantation.
+The patient has received, or is receiving, allogeneic Stem Cell Transplantation (SCT).
+Previous allogenic stem cell or allogeneic bone marrow transplantation
+The patient has received, or is receiving induction chemotherapy followed by Stem Cell Transplantation.
+The patient declines to undergo stem cell transplantation or
+Stem cell transplantation is not available to the patient due to cost or other reasons
+Prior allogeneic marrow or stem cell transplantation
+Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Prior allogeneic bone marrow or organ transplantation
+Patients who have received a prior solid organ transplantation are not eligible
+Prior autologous stem cell transplantation < 1 month or allogenic stem cell transplantation < 3 months prior to C1D1.
+History of allogeneic bone marrow or stem cell transplantation
+Prior allogeneic hematopoietic stem-cell transplantation if evidence of donor chimerism persists; patients with exclusively autologous hematopoiesis are eligible
+History of primary immunodeficiency, allogeneic bone marrow transplantation, solid organ transplantation, or previous clinical diagnosis of tuberculosis
+Subject is not a candidate to undergo allogenic hematopoietic stem cell transplantation (HSCT).
+Subject has received allogeneic HSCT or solid organ transplantation.
+Prior organ transplantation including allogeneic stem-cell transplantation
+Prior allogeneic or autologous bone marrow transplantation or other solid organ transplantation.
+All patients must have a histologic or cytological diagnosis of ALL treated with stem cell transplantation; there are no restrictions on prior therapy
+Any patient undergoing allogeneic hematopoietic stem cell transplantation (either 1st or subsequent)
+Scheduled to receive conditioning chemotherapy followed by upfront or salvage autologous peripheral blood hematopoietic stem cell transplantation
+Patients who have undergone a prior allogeneic or autologous stem cell transplantation within the previous six months
+Patient has CMV specific T-cells from the donor of his/her hematopoietic stem cell transplantation (HSCT) available
+Patients designated to undergo myeloablative or intermediate intensity allogeneic peripheral blood or bone marrow hematopoietic cell transplantation; consent will be obtained prior to admission for HSCT; patients receiving any donor source of stem cells are eligible; eligible conditioning regimens are those defined as myeloablative by the American Society of Blood and Marrow Transplantation (ASBMT) consensus criteria as well as the combination of fludarabine with melphalan (100-140 mg/mg^2)
+Undergoing hematopoietic stem cell transplantation (HSCT) at the University of Wisconsin Carbone Cancer Center (UWCCC)
+Participants with prior allogeneic bone marrow transplantation or prior solid organ transplantation
+Prior allogenic bone marrow transplantation or prior solid organ transplantation
+Patients who have undergone prior allogeneic transplantation are eligible provided that their transplant day 0 is > 6 months from their first dose of study drug
+Not eligible for stem cell transplantation
+Recipients of allogeneic hematopoietic cell transplantation (HCT) after either myeloablative or reduced intensity conditioning regimens; any donor source of stem cells is eligible
+Stem cell transplantation within preceding 60 days prior to registration
+Recipients of allogeneic hematopoietic cell transplantation (HCT) after either myeloablative or reduced intensity conditioning regimens; any donor source of stem cells is eligible
+Transplantation of PBSC
+Previous allogeneic hematopoietic stem cell transplantation
+Subject underwent allogeneic stem cell transplantation at least 6 months prior to enrollment
+Prior allogeneic transplantation
+Patients must have a hematologic malignancy for which allogeneic hematopoietic peripheral blood cell transplantation is deemed clinically appropriate. Eligible diseases and stages include the following:
+History of major organ transplantation with an existing functional graft
+Patients who have undergone either ablative or non-myeloablative allogeneic stem cell transplantation are eligible
+Allogeneic stem cell transplantation using a single or multiple umbilical cord blood units or using bone marrow
+Allogeneic stem cell transplantation using in vivo or ex vivo T cell depletion, either by cell manipulation or with T cell depleting antibodies (any anti-thymocyte globulin preparation or alemtuzumab given within 30 days of transplantation)
+Prior allogeneic hematopoietic cell transplantation (HCT)
+Subjects undergoing matched related full intensity allogeneic hematopoietic stem cell transplantation (HSCT)
+Patients must otherwise fulfill institutional criteria for eligibility to undergo myeloablative allogeneic stem cell transplantation
+Patients who have undergone allogeneic stem cell transplantation for the treatment of any hematological malignancy are eligible
+Hematologic disorder requiring allogeneic hematopoietic cell transplantation
+Transplantation with PBSC
+Prior allogeneic hematopoietic stem cell transplantation
+Subjects with hematologic malignancies or recipients of a first allogeneic or autologous hematopoietic stem cell transplantation and presently clinically stable
+Prior allogeneic transplantation
+Individual with history of any organ transplantation
+Patients who have had stem-cell transplantation
+Prior stem cell transplantation
+Eligible for haploidentical stem cell transplantation according to the investigator
+History of prior allogeneic hematopoietic stem cell transplantation or prior solid organ transplantation
+Prior history of allogeneic bone marrow, stem-cell, or solid organ transplantation
+Prior allogeneic stem cell or solid organ transplantation
+Autologous stem cell transplantation less than 90 days prior to study day 1
+Prior allogeneic stem cell or solid organ transplantation
+Prior autologous stem cell transplantation < 1 month or allogeneic stem cell transplantation < 4 months prior to C1D1.
+Has received hematopoietic stem cell transplantation (HSCT) within 60 days of the first dose of DS-3201b
+Patients must not have had prior stem cell transplantation (autologous or allogeneic)
+Immunocompromised (due to conditions including HIV infection, hematopoietic-cell or solid organ transplantation, and chronic glucocorticoid use) men and women of any ethnic group aged ?18 years.
+Patients with history of allogeneic stem cell transplantation
+Patients who have previously received a prior organ transplantation, including allogeneic stem cell transplantation
+History of prior allogeneic bone marrow/stem-cell or solid organ transplantation.
+Patients receiving autologous stem cell transplantation must wait 8 weeks before initiation of study drug administration.
+Prior organ transplantation, including allogeneic stem cell transplantation
+Solid organ transplantation requiring immunosuppression
+Prior organ transplantation, including allogeneic stem cell transplantation
+Patients who have previously undergone hematopoietic stem cell transplantation (SCT) or who are scheduled for SCT
+Prior autologous or allogeneic stem cell transplantation (SCT) within 12 weeks of initiation of study treatment
+History of allogeneic stem cell transplantation
+Not a candidate for or refusing treatment with hematopoietic stem cell transplantation
+Prior allogeneic stem cell or solid organ transplantation
+Prior intensive chemotherapy or stem cell transplantation for the treatment of myelodysplastic syndrome
+Participants with prior allogeneic stem cell or solid organ transplantation
+Not a candidate for, or refusing treatment with hematopoietic stem cell transplantation